Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Comparative claims
-
According to the code, is it permissible to develop a promotional piece that would be submitted for PAAB review that compared the sponsor's drug product to another product not available in Canada? As the individual molecules of the other combination product not available are used in Canadian medical practice. The fact that the specific drug is not available in Canada can be mentioned. Thank you.
-
Per PAAB code section 5.1, compared drugs should have an authorized indication for use in common. A product that is not available in Canada would not have terms of market authorization for use so the comparison would not be acceptable in advertising.
Please also note that the Health Canada Therapeutic Comparative Advertising document also requires compared health products to have received marketing authorization in the form of a Notice of Compliance(NOC) and/or a Drug Identification Number (DIN) for therapeutic comparisons.
-
@jennifer-carroll Thank you!
